Glancy Prongay & Murray Commences Investigation on Behalf of Unilife Corporation Investors

LOS ANGELES--(BUSINESS WIRE)--

Glancy Prongay & Murray LLP ("GPM") announces an investigation on behalf of investors of Unilife Corporation ("Unilife" or the "Company") UNIS concerning the Company and its officers' possible violations of federal securities laws. GPM is preparing a lawsuit on behalf of injured investors.

Unilife designs, manufactures, and supplies injectable drug delivery systems in the United States and internationally. The Company announced on May 9, 2016, that it was postponing its earnings call due to discovery of violations of company policy and possible violations of laws by the former Unilife CEO; and, that the Company is investigating these issues and potential effect on financial reporting and internal controls. On this news the Company's shares fell sharply in value.

On May 23, 2016, Unilife announced that it has received a deficiency letter from NASDAQ for failing to file its financial reports within the required period. On this news, shares of Unilife have fallen over 11% to just $2.61 per share during intra-day trading on May 24, 2016.

If you purchased Unilife securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160524006487/en/